An activation of LC3A-mediated autophagy contributes tode novoand acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Abstract 742: Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

10.1158/1538-7445.am2015-742 ◽

2015 ◽

Author(s):

Yuho Maki ◽

Shinsuke Hashida ◽

Hiromasa Yamamoto ◽

Kazuhiko Shien ◽

Tomoaki Ohtsuka ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Cell Lines ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Hsp90 Inhibitor ◽

Adenocarcinoma Cell ◽

Egfr Tyrosine Kinase ◽

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung Adenocarcinoma

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2012.07.166 ◽

2012 ◽

Vol 84 (3) ◽

pp. S102

Author(s):

H. Hirata ◽

K. Nakamura ◽

N. Kunitake ◽

Y. Shioyama ◽

T. Sasaki ◽

...

Keyword(s):

Radiation Therapy ◽

Brain Metastases ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors ◽

Egfr Mutant

High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma

Oncotarget ◽

10.18632/oncotarget.19777 ◽

2017 ◽

Vol 8 (35) ◽

pp. 59000-59007 ◽

Cited By ~ 3

Author(s):

Youyou Xie ◽

Dongqing Lv ◽

Wei Wang ◽

Minhua Ye ◽

Xiaofeng Chen ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Expression Levels ◽

Egfr Tyrosine Kinase ◽

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

Cancer Biology & Therapy ◽

10.4161/cbt.9.8.11881 ◽

2010 ◽

Vol 9 (8) ◽

pp. 572-582 ◽

Cited By ~ 39

Author(s):

Yan Xu ◽

Hongyu Liu ◽

Jun Chen ◽

Qinghua Zhou

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

P1.02-050 Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.11.634 ◽

2017 ◽

Vol 12 (1) ◽

pp. S517-S518

Author(s):

Andrés Cardona ◽

Oscar Arrieta ◽

Leonardo Rojas ◽

Beatriz Wills ◽

Noemi Reguart ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors ◽

Egfr Mutant

P76.85 Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1142 ◽

2021 ◽

Vol 16 (3) ◽

pp. S626

Author(s):

S. Padda ◽

J. Whisenant ◽

J. Neal ◽

S. York ◽

W. Iams ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Egfr Tyrosine Kinase Inhibitors ◽

Egfr Mutant

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

BMC Cancer ◽

10.1186/s12885-020-06920-3 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Svenja Wagener-Ryczek ◽

Carina Heydt ◽

Juliane Süptitz ◽

Sebastian Michels ◽

Markus Falk ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Acquired Resistance ◽

Mutational Spectrum ◽

Egfr Tyrosine Kinase ◽

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors

Thoracic Cancer ◽

10.1111/1759-7714.12814 ◽

2018 ◽

Vol 9 (9) ◽

pp. 1151-1155 ◽

Cited By ~ 3

Author(s):

Zhansheng Jiang ◽

Yu Zhang ◽

Yinli Yang ◽

Zhensong Yue ◽

Zhanyu Pan

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitors ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma

Current Drug Discovery Technologies ◽

10.2174/1570163813666160524142846 ◽

2016 ◽

Vol 13 (2) ◽

pp. 68-76 ◽

Cited By ~ 6

Author(s):

Akash Verma ◽

Akhil Chopra ◽

Yeo W. Lee ◽

Lavina D. Bharwani ◽

Atasha B. Asmat ◽

...

Keyword(s):

Pleural Effusion ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Malignant Pleural Effusion ◽

Kinase Inhibitors ◽

Talc Pleurodesis ◽

Egfr Tyrosine Kinase ◽

Abstract 77: Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors

10.1158/1538-7445.am2019-77 ◽

2019 ◽

Author(s):

Yiting Li ◽

Guoqing Qian ◽

Taofeek K. Owonikoko ◽

Suresh S. Ramalingam ◽

Shi-Yong Sun

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Therapeutic Potential ◽

Acquired Resistance ◽

Third Generation ◽

Egfr Tyrosine Kinase ◽